This Week in Otolaryngology — May 21, 2026

Welcome to This Week in Otolaryngology. This week we're covering 10 notable papers spanning tinnitus management, advances in otology and neurotology, new data in head and neck oncology, and updates in rhinology and sleep medicine. Let's dive in.

We begin this week with tinnitus, a condition affecting roughly one in seven adults.

A comprehensive primer in *Nature Reviews Disease Primers* provides a state-of-the-art overview of the condition [1]. It reminds us that tinnitus is a complex process involving cochlear injury, central gain, and maladaptive plasticity, often modulated by stress and emotion. The authors reinforce that tinnitus-focused counseling and cognitive behavioral therapy remain first-line treatments. They also note the promise of emerging therapies like neuromodulation.

On that very topic, a systematic review and meta-analysis in *The Laryngoscope* evaluates the evidence for these approaches [2].

The Study

Investigators analyzed 26 randomized controlled trials including over 1,500 patients, looking at techniques like transcranial electrical stimulation, repetitive TMS, vagus nerve stimulation, and bimodal stimulation.

Results

The findings bring some much-needed clarity. For two of the most discussed modalities, transcranial direct current stimulation (tDCS) and repetitive TMS (rTMS), the pooled analysis showed a nonsignificant effect on tinnitus severity compared to sham treatment. In contrast, bimodal stimulation—which combines sound and electrical somatosensory stimulation—yielded consistent and clinically meaningful reductions in tinnitus severity scores, with benefits lasting up to 12 months. Adverse events for noninvasive methods were generally mild and transient.

Clinical Implications

This meta-analysis suggests that among the various neuromodulation techniques, bimodal stimulation currently has the strongest evidence base for providing durable relief. While other methods may hold promise, this paper tempers expectations for tDCS and rTMS based on the current body of randomized trial data.

Next, we turn to a series of papers in otology and neurotology, covering genetics, surgery, and quality of life.

First, from *Otology & Neurotology*, a study uses a genotype-guided approach to characterize hearing loss in adults with a common East Asian genetic variant [7].

The Study

Researchers in Taiwan recruited adults who were homozygous for the GJB2 p.V37I variant and compared them to genotype-negative controls.

Findings

They identified a distinct audiometric phenotype: homozygotes showed bilateral, symmetric, high-frequency-predominant hearing loss. The odds of having abnormal hearing were more than seven times higher in this group compared to controls. While tinnitus was also more common in homozygotes, after statistical adjustment, it was found to be independently associated with noise exposure, not the genotype itself.

Clinical Implications

This work delineates a recognizable adult phenotype for this genotype, which can guide counseling and suggests the need for longitudinal surveillance in these individuals, as the hearing loss appears to be age-dependent.

Staying in the realm of hearing but shifting to intervention, another paper in *Otology & Neurotology* examines long-term functional hearing preservation in pediatric cochlear implant recipients [9].

The Study

This was a retrospective review of 113 pediatric cases at a tertiary center, all of whom had usable low-frequency hearing before implantation. The key outcome was functional hearing preservation, defined as a postoperative unaided threshold of 80 dB or better at 250 Hz.

Results

The overall probability of maintaining functional hearing was 70% at one year and 57% at five years. A critical finding was the impact of inner ear malformations. Children with an enlarged vestibular aqueduct, or EVA, had very poor outcomes, with almost no chance of preserving functional hearing beyond two years. In contrast, for those without EVA, the five-year preservation rate was over 60%. The study also found that shorter electrode arrays were associated with better preservation.

Clinical Implications

These data are invaluable for counseling families. They confirm that long-term hearing preservation is a realistic goal for many children, but they also highlight the significant challenge posed by EVA. The findings support tailoring surgical strategy, such as electrode choice, when hearing preservation is the objective.

Our final paper in this section, also from *Otology & Neurotology*, assesses quality of life in patients with vestibular schwannoma based on their management strategy [10].

The Study

Using the new Mayo Clinic Vestibular Schwannoma Quality of Life Index, researchers performed a cross-sectional assessment of 652 patients managed with either observation, radiation, or microsurgery.

Results

At a mean follow-up of over six years, there were significant and clinically meaningful differences between the groups. The observation group reported the highest quality of life, followed by the radiation group, with the microsurgery group reporting the lowest scores. The difference in global quality of life between the surgery and observation groups exceeded the threshold for a minimal important difference. Similar clinically significant differences were seen in the hearing problems domain.

Clinical Implications

These findings provide robust, patient-centered data to guide counseling. They quantify the quality-of-life impact associated with different management strategies, reinforcing that active treatment, particularly surgery, comes with a quantifiable trade-off that patients must consider.

In head and neck oncology, we have important updates on screening, surgical risk stratification, and patient selection.

First, a study in *JAMA Otolaryngology–Head & Neck Surgery* evaluates a novel antibody test for early detection of nasopharyngeal carcinoma, or NPC [3].

The Study

This multicenter case-control study from Taiwan compared a new test for antibodies against the EBV protein P85 with established markers, including EBV IgA scores and circulating EBV DNA.

Results

The new P85-Ab test demonstrated excellent performance, with a sensitivity of 92.5% and a specificity of 98.7%. Crucially, its sensitivity for detecting early-stage NPC was higher than the other two methods, at 93% versus 87%. This translated to a higher positive predictive value, especially in higher-incidence scenarios.

Clinical Implications

These findings support the P85-Ab test as a powerful and potentially superior biomarker for population-based screening for NPC, with a particular advantage in detecting disease at its earliest and most curable stages.

Moving from screening to surgical management, a large multicenter study in *Head & Neck* quantifies the risk of cervical metastasis in primary parotid gland malignancies [6].

The Study

Investigators retrospectively analyzed 380 patients from 17 centers who underwent parotidectomy with a concurrent neck dissection.

Findings

Pathologically confirmed neck metastases were found in about one-quarter of patients. Level II was the most frequently involved station. On multivariate analysis, the two independent predictors of nodal metastasis were high histological grade and the presence of lymphovascular invasion, or LVI. For example, salivary duct carcinoma, a high-grade histology, had a nodal metastasis rate of nearly 60%.

Clinical Implications

This paper provides strong evidence to guide decisions about elective neck management. For patients with high-grade parotid cancers or those with LVI on pathology, the risk of occult metastasis is substantial, supporting a more aggressive, risk-adapted approach to treating the neck.

Finally in oncology, a paper from *Head & Neck* uses a sophisticated statistical analysis to challenge a common bias in treating glottic cancer [8].

The Study

Researchers analyzed outcomes in 676 patients treated with transoral laser microsurgery, or TOLMS. They specifically asked whether chronological age impacts cancer-specific mortality, using a competing-risks model.

Results

The analysis confirmed that older patients had worse overall survival. However, this was almost entirely driven by an increased risk of dying from other, non-cancer causes. When the analysis properly accounted for these competing risks, age had no significant influence on the probability of dying from laryngeal cancer. The factors that did predict cancer death were tumor-related: pT category and margin status.

Clinical Implications

This is a powerful and practice-affirming finding. It provides clear evidence that treatment decisions for glottic cancer should be based on tumor biology and patient fitness, not on chronological age alone. An otherwise fit older patient should be offered the same curative-intent TOLMS as a younger patient with a similar tumor.

Our final section covers two key papers, one in sleep medicine and one in rhinology.

First, a secondary analysis of the STAR trial, published in *JAMA Otolaryngology–Head & Neck Surgery*, proposes a new way to think about success after hypoglossal nerve stimulation for obstructive sleep apnea [4].

The Study

Instead of focusing solely on the Apnea-Hypopnea Index, or AHI, the authors re-analyzed the trial data looking at hypoxic burden, a measure of the total time spent with low oxygen levels.

Findings

The results are striking. Hypoglossal nerve stimulation led to a median reduction in hypoxic burden of over 76%. More importantly, improvement in daytime sleepiness, as measured by the Epworth Sleepiness Scale, was significantly associated with the reduction in hypoxic burden, but not with the reduction in AHI. Perhaps most compelling, a large proportion of patients who were considered 'non-responders' by traditional AHI criteria still achieved a transition from high to low hypoxic burden.

Clinical Implications

This study challenges the supremacy of the AHI as the sole metric of treatment success. It suggests that hypoxic burden may be a more physiologically relevant endpoint that better reflects patient outcomes. For clinicians managing these patients, it means that even if the post-treatment AHI is not perfect, a patient may be deriving substantial physiologic benefit that is better captured by looking at their hypoxic burden.

Finally, from the airway to the sinuses, a study in the journal *Rhinology* provides a timely economic analysis of treatments for severe chronic rhinosinusitis with nasal polyps [5].

The Study

This analysis, from the perspective of the Spanish National Health System, compared the cost-effectiveness of endoscopic sinus surgery, or ESS, with biologic therapy.

Results

In terms of effectiveness, both strategies achieved similar, significant improvements in SNOT-22 scores at two years. The costs, however, were dramatically different. The two-year cost for ESS was roughly €5,300, compared to over €27,000 for biologics. This made biologics far from cost-effective in the short term. Even with a 10-year projection, biologics only began to approach accepted cost-effectiveness thresholds under assumptions of a major price reduction of around 40%.

Clinical Implications

This paper provides strong economic support for the current treatment paradigm. ESS is the more efficient and less costly initial strategy for most patients. While biologics are highly effective, their current price point makes them most appropriate as a second-line therapy for patients who have failed or have contraindications to surgery.

If you only have time for one paper this week, make it the secondary analysis of the STAR trial in *JAMA Otolaryngology–Head & Neck Surgery* [4]. It argues convincingly that hypoxic burden, not just AHI, is a critical metric for assessing the success of hypoglossal nerve stimulation, and may better correlate with patient-reported outcomes like sleepiness.

Here are the key takeaways from this week in Otolaryngology:

First, for tinnitus, bimodal neuromodulation has the strongest evidence for consistent and durable benefit among emerging therapies, while pooled data for rTMS and tDCS are less convincing [2].

Second, in sleep apnea patients with hypoglossal nerve stimulators, look beyond the AHI. Hypoxic burden is a crucial metric that correlates with sleepiness and may show significant improvement even in AHI 'non-responders' [4].

Third, in head and neck oncology, do not let chronological age dictate treatment for early glottic cancer; base TOLMS decisions on tumor factors [8]. And for parotid cancer, strongly consider elective neck management in patients with high-grade histology or lymphovascular invasion [6].

Fourth, for vestibular schwannoma, new quality of life data show that observation is associated with the highest scores and surgery with the lowest, providing crucial data for shared decision-making [10].

Finally, in managing severe nasal polyps, endoscopic sinus surgery remains the most cost-effective initial strategy, with expensive biologics best reserved for refractory cases from a health system perspective [5].

That's your roundup for This Week in Otolaryngology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.